Gara Jalqabaatti › Kansaar Onnee Triple-Negative › Massachusetts › Boston
Qorannoo klinikaalii Kansaar Onnee Triple-Negative Boston, MA keessatti
Qorannoo 26 Kansaar Onnee Triple-Negative f Boston fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Massachusetts General Hospital, Boston
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Namoota walitti qabaa jiraSadarkaa 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Dana Farber Cancer Institute, Boston
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Dana-Farber Cancer Institute, Boston
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Namoota walitti qabaa jiraSadarkaa 3
- Massachusetts General Hospital Cancer Center ( Site 0091), Boston
- Dana Farber Cancer Institute ( Site 0090), Boston
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Nurse-Led, Coping and Supportive Intervention for Patients With Triple-Negative Breast Cancer
Namoota walitti qabaa jira
- Massachusetts General Hospital, Boston
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Namoota walitti qabaa jiraSadarkaa 3
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Dana-Farber Cancer Institute, Boston
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Normunity Investigational Site, Boston
- Normunity Investigational Site, Boston
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
Namoota walitti qabaa jiraSadarkaa 1
- Dana-Farber Cancer Institute, Boston
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Namoota walitti qabaa jiraSadarkaa 2/3
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
Namoota walitti qabaa jiraSadarkaa 2
- Dana-Farber Cancer Institute, Boston
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Namoota walitti qabaa jiraSadarkaa 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Namoota walitti qabaa jiraSadarkaa 1
- Massachusetts General Hospital, Boston
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Namoota walitti qabaa jiraSadarkaa 1
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Sacituzumab Govitecan In TNBC
Namoota walitti qabaa jiraSadarkaa 2
- Dana Farber Cancer Institute, Boston
- Massachusetts General Hospital, Boston
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Dana-Farber Cancer Institute, Boston
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study of LY4175408 in Participants With Advanced Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Massachusetts General Hospital, Boston
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Namoota walitti qabaa jiraSadarkaa 2
- Dana-Farber Cancer Institute, Boston
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
Namoota walitti qabaa jiraSadarkaa 2
- Dana Farber Cancer Institute, Boston
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Dana Farber Cancer Institute, Boston
A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
Namoota walitti qabaa jiraSadarkaa 1
- Massachusetts General Hospital, Boston
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Namoota walitti qabaa jiraSadarkaa 1/2
- Massachusetts General Hospital, Boston
Qorannoo Kansaar Onnee Triple-Negative magaalota biroo keessatti
- Houston, TXQorannoo 42
- New York City, NYQorannoo 31
- Nashville, TNQorannoo 28
- Los Angeles, CAQorannoo 27
- San Antonio, TXQorannoo 23
- St. Louis, MOQorannoo 21
- Arlington, VAQorannoo 20
- Atlanta, GAQorannoo 20
- Dallas, TXQorannoo 18
- Chicago, ILQorannoo 16
- Columbus, OHQorannoo 16
- Grand Rapids, MIQorannoo 15
Qorannoo biroo Boston keessatti
- Saree OljooQorannoo 112
- Kansara Qara'a Non-Small CellQorannoo 90
- Saree (Gosoota Hunda)Qorannoo 85
- Kansara MetastatikiiQorannoo 63
- Kansarii ColorectalQorannoo 63
- Dhibee QaraQorannoo 62
- Kansarii OvariiQorannoo 61
- Kansarii ProstateQorannoo 59
- DepreshiniiQorannoo 52
- Kansa EndometiriyaaliiQorannoo 50
- Cufama OnneeQorannoo 44
- Leukemia Myeloidii HamaaQorannoo 44
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.